Valuation: Novartis AG

Market Cap 283B 248B 230B 212B 399B 27,252B 404B 2,743B 1,073B 13,356B 1,062B 1,039B 46,114B P/E 2026 *
22x
P/E 2027 * 18.3x
Enterprise Value 315B 276B 256B 235B 444B 30,337B 449B 3,053B 1,195B 14,868B 1,182B 1,157B 51,334B EV / Sales 2026 *
5.47x
EV / Sales 2027 * 5.14x
Free-Float
91.66%
Yield 2026 *
2.81%
Yield 2027 * 2.98%
1 day-0.59%
1 week+2.46%
Current month-1.15%
1 month+5.87%
3 months+7.26%
6 months+10.30%
Current year+14.65%
1 week 131.5
Extreme 131.5
137.2
1 month 131.3
Extreme 131.3
140.36
Current year 116
Extreme 116
144.12
1 year 96.75
Extreme 96.75
144.12
3 years 94
Extreme 94
144.12
5 years 94
Extreme 94
144.12
10 years 61.7
Extreme 61.7
144.12
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Chief Tech/Sci/R&D Officer 64 2022-05-15
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%+2.46% - - 283B
+2.49%+1.98%+54.22%+154.40% 1,048B
+0.72%-1.28%+52.48%+47.25% 603B
+1.07%+4.62%+38.54%+78.17% 452B
+0.63%+2.08%+30.59%+21.56% 327B
+0.90%+1.04%+22.09%+15.99% 259B
-1.20%+1.36%-21.14%-41.57% 219B
+0.57%+3.09%+23.78%+55.97% 198B
-2.20%+0.18%+20.32%+61.56% 162B
+0.77%+2.85%+2.80%-33.32% 142B
Average -0.33%+1.77%+24.85%+40.00% 378.99B
Weighted average by Cap. -0.43%+1.67%+36.77%+71.57%

Financials

2026 *2027 *
Net sales 57.64B 50.52B 46.81B 43.08B 81.24B 5,551B 82.23B 559B 219B 2,720B 216B 212B 9,393B 60.46B 52.99B 49.1B 45.19B 85.22B 5,823B 86.25B 586B 229B 2,854B 227B 222B 9,853B
Net income 13.06B 11.45B 10.61B 9.76B 18.41B 1,258B 18.63B 127B 49.54B 617B 49.03B 47.98B 2,129B 15.66B 13.73B 12.72B 11.71B 22.08B 1,508B 22.34B 152B 59.41B 739B 58.8B 57.53B 2,553B
Net Debt 32.03B 28.08B 26.02B 23.94B 45.15B 3,085B 45.7B 310B 122B 1,512B 120B 118B 5,220B 27.82B 24.39B 22.6B 20.8B 39.22B 2,680B 39.69B 270B 106B 1,313B 104B 102B 4,534B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
26-07-20 135.56 +2.40% 10,157
26-07-20 €132.38 -2.11% 2,675
26-07-17 €135.24 +1.52% 1,996
26-07-16 €133.22 +0.68% 1,341
26-07-15 €132.32 +0.02% 1,703
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
154.58USD
Average target price
152.19USD
Spread / Average Target
-1.55%

Quarterly revenue - Rate of surprise